BioSpace News Archive

Genetown

Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

With the Series A financing, the company now has now raised a total of $50.5 million to support its mission.

May 13, 2020
·
3 min read
·
Alex Keown
Genetown

GreenLight Biosciences Raises $17 Million to Scale Up COVID-19 Vaccine Manufacturing

GreenLight Biosciences closed an oversubscribed $17 million “special purpose funding round” in order to expand its scalable mRNA manufacturing capability for its mRNA COVID-19 vaccine. The goal is to be able to produce billions of doses.

May 13, 2020
·
3 min read
·
Mark Terry
Policy

Moderna’s Phase II-Ready COVID-19 Vaccine Candidate Snags Fast Track Designation

The designation will expedite regulatory review of the medication should it prove to be safe and effective.

May 13, 2020
·
2 min read
·
Alex Keown
Business

Icosavax’s Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV

“VLPs have special immunological properties and are processed differently by the immune system so they have longer duration,” Adam Simpson, CEO of Icosavax, told BioSpace.

May 13, 2020
·
4 min read
·
Gail Dutton
Drug Development

Biopharma Update on the Novel Coronavirus: May 13

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 13, 2020.

May 13, 2020
·
3 min read
·
BioSpace Editorial Staff
Policy

Celgene CVR Holders Uncertain After FDA Refuses Review of BMS and bluebird’s Multiple Myeloma Therapy

This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma.

May 13, 2020
·
2 min read
·
Alex Keown
Policy

COVID-19 Pandemic Leaves Pharmaceutical Companies Vulnerable to Cyber Criminals

Although many cyber criminals have pledged not to attack healthcare providers during the COVID-19 pandemic, one expert tells CNBC that this may not extend to pharmaceutical companies.

May 13, 2020
·
3 min read
·
Krystle Vermes
BioSpace Global Roundup, May 14

Biopharma and life sciences companies from across the globe provide updates on their pipeline and business.

May 13, 2020
·
4 min read
·
Alex Keown
Business

Gilead Inks Manufacturing Deals to Make COVID-19 Drug Remdesivir Available in 127 Countries

Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”

May 13, 2020
·
3 min read
·
Mark Terry
Drug Development

American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma

ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease

May 13, 2020
·
7 min read